MarginsXMarginsX
Home › Markets › Consumer Staples › GRDN

Guardian Pharmacy Services Inc. (GRDN)

GRDN trades on NYSE in Consumer Staples, Retail-Drug Stores and Proprietary Stores. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$49.43
-0.18% on the day
Market cap
$3.1B
Mid cap
Revenue · 2025
$1.4B
+17.9% on 2024
Net income · 2025
$49.2M
3.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1802255/000119312526102172/0001193125-26-102172-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGRDN on NYSE
SectorConsumer Staples
IndustryRetail-Drug Stores and Proprietary Stores
CountryUnited States
IPO year2024
SEC CIK0001802255
SEC industry codeRetail-Drug Stores and Proprietary Stores
Incorporated inGA

Financials · 2025

LineValue
Revenue$1.4B
Net income$49.2M
Operating income$72.7M
Net margin3.4%
Operating margin5.0%
Revenue growth+17.9%
Cash$65.6M
Total assets$412.7M
P/E (computed)63.6×
P/S (computed)2.2×

Warning signs

Cash runway
Cash-flow positive
$119.7M cash at September 30, 2026
Share count, 1 year
+0.1%
2025-10-31 to 2026-11-03
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$174.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$119.7M cash; operating cash flow $28.5M a quarter.Report 2026-09-30
Shares outstanding63,353,919 (2026-11-03); 63,320,634 a year earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-03-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Atlanta, Georgia, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $100K, sold $174.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$371.1M$18.7M$43.4M$119.7MNo debt tags$1.5B10-Q 2026-11-05
Q2 2026
2026-06-30
$351.8M$21.9M$30.0M$89.8MNo debt tags$1.5B10-Q 2026-08-06
Q1 2026
2026-03-31
$336.6M$13.3M$6.1M$64.9MNo debt tags$1.5B10-Q 2026-05-06
Q4 2025
2025-12-31
$397.6M$20.9M$34.6M$65.6M$0$1.4B10-K 2026-03-11
Q3 2025
2025-09-30
$377.4M$9.8M$28.2M$36.5MNo debt tags$1.4B10-Q 2026-11-05
Q2 2025
2025-06-30
$344.3M$9.0M$19.9M$18.8MNo debt tags$1.3B10-Q 2026-08-06
Q1 2025
2025-03-31
$329.3M$9.4M$17.6M$14.0MNo debt tags$1.3B10-Q 2026-05-06
Q4 2024
2024-12-31
$338.6M$11.9M$22.3M$4.7M$0$1.2B10-K 2026-03-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-05-06
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-03-26

Source: SEC EDGAR submissions feed, 226 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+16.8%
1 month+24.4%
3 months+28.8%
Year to date+64.6%
1 year+62.8%
From 52-week high-0.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Retail-Drug Stores and Proprietary Stores

TickerCompanyPriceDayMarket cap
CVSCVS Health Corporation$88.59-0.85%$113.3B
YI111 Inc.$2.84-0.35%$25.0M
PETSPetMed Express Inc.$0.8977-4.52%$20.0M
RDGTRidgetech Inc.$1.01-4.72%$3.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier